TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00712725
Drug: MK3207- 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: MK3207 2.5 mg taken after migraine onset.
Study: NCT00712725
Drug: MK3207- 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2: MK3207 5 mg taken after migraine onset.
Study: NCT00712725
Drug: MK3207- 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 3: MK3207 10 mg taken after migraine onset.
Study: NCT00712725
Drug: MK3207- 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 4: MK3207 20 mg taken after migraine onset.
Study: NCT00712725
Drug: MK3207- 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 5: MK3207 50 mg taken after migraine onset.
Study: NCT00712725
Drug: MK3207- 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 6: MK3207 100 mg taken after migraine onset.
Study: NCT00712725
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken after migraine onset.
Study: NCT04801433
Drug: Capotetriol scalp solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
Study: NCT01329276
Drug: Symbicort® forte Turbohaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 µg budesonide / 9 µg formoterol fumarate dihydrate
Study: NCT00599534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg tablets
Study: NCT00054327
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04044053
Drug: PF-06865571 400 mg Immediate Release (IR) in Fed State
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg IR dose in fed state
Study: NCT04044053
Drug: PF-06865571 400 mg MR in Fed State
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg MR in fed state
Study: NCT04044053
Drug: PF-06865571 400 mg MR in Fasted State
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg MR in fasted state
Study: NCT01195376
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02780583
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injection administered every 6 hours along with intravenous methylprednisolone
Study: NCT01700998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01841125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 15mg, QD(once a day), Oral medication
Study: NCT00107315
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03359785
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Tablets.
Study: NCT02141698
Drug: TAK-438 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets
Study: NCT01713673
Drug: Ulthera System Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT01713673
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment using the Ulthera System, but delivering no ultrasound energy.
Study: NCT01024972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: equiosmolar volume (5% mannitol) every 6 hours x 7 days
Study: NCT00004112
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, vincristine and doxorubicin as a drip into the bloodstream (intravenously) and prednisolone (steroid) as tablets taken with or after food.
Study: NCT00004112
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004112
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01777217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGRT with placebo
Study: NCT03401944
Drug: TPN
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00503412
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral 14C
Study: NCT00607399
Drug: SGX523 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a dose escalation study
Study: NCT00086411
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch containing no nicotine
Study: NCT01027234
Drug: AZD8418
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT01027234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT00042666
Drug: LY317615
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg, oral, QD, up to six 28 day cycles
Study: NCT00003783
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003783
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003783
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003783
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00904462
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
Study: NCT01560637
Drug: UT-15C (treprostinil diolamine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UT-15C extended release oral tablet three times daily
Study: NCT00064259
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01380535
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
Study: NCT01579565
Drug: OMS302
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Study: NCT01579565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Study: NCT01359241
Drug: Usual diabetes treatment regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual non-insulin glucose lowering medications
Study: NCT03881904
Drug: 0.075mg gestodene/0.03mg ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.
Study: NCT02987907
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: use normal saline 2ml I.A. during TACE
Study: NCT03887455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly (once every 2 weeks) administered as i.v. infusion.
Study: NCT03303989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
Study: NCT02363725
Drug: Colchimax®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02363725
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00142948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02334150
Drug: CSEA (ropivocaine and sufentanil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
Study: NCT04140695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT05345574
Drug: remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil as anaesthetic adjuvant
Study: NCT02764541
Drug: Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04420130
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.
Study: NCT00851318
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate dose between 6 to 8 mg/week.
Study: NCT02589665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00728208
Drug: GSK372475
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5mg for 28 days
Study: NCT01438008
Drug: Placebo po
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure
Study: NCT01559922
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of up to 2 study treatments administered 6 weeks apart
Study: NCT01432145
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.
Study: NCT00664560
Drug: PN 400 (VIMOVO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg naproxen/20 mg esomeprazole bid
Study: NCT00664560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill bid
Study: NCT00664560
Drug: Rescue Antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid Tablets
Study: NCT01853579
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
Study: NCT01853579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Study: NCT00150319
Drug: Vfend®; I.V.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01814878
Drug: Tramadol HCl/Acetaminophen ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of ER (tramadol HCl \[75 mg\]/acetaminophen \[650 mg\]) will be administered at 0, 12, 24 and 36 hours
Study: NCT01814878
Drug: Tramadol HCl/Acetaminophen IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of IR (tramadol HCl \[37.5 mg\]/acetaminophen \[325 mg\]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
Study: NCT03645421
Drug: MEDI0382 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose
Study: NCT03645421
Drug: MEDI0382 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose
Study: NCT03645421
Drug: MEDI0382 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose
Study: NCT03645421
Drug: PlaceboA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL liquid formulation per Vial
Study: NCT03645421
Drug: MEDI0382 50 ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, 1.0 mL per vial, 50 ug
Study: NCT03645421
Drug: PlaceboB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection in 1.0 mL pre-filled syringe.
Study: NCT03139981
Drug: ASN002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of ASN002 for 28 days
Study: NCT03139981
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for ASN002 for 28 days
Study: NCT00484393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo applied prior to 1 injection
Study: NCT00549263
Drug: SB797620
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01549886
Drug: Y-90-Zevalin
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
Study: NCT04225052
Drug: YHP1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: YHP1903 Tab. 1mg
Study: NCT01952548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02975999
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
Study: NCT00856908
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolerable dose given twice daily
Study: NCT00856908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolerable dose given twice daily
Study: NCT01813994
Drug: Arm1: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection.
Study: NCT00634725
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03550443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing an inert placebo
Study: NCT01106859
Drug: Placebo (sublingual tablet)
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
Study: NCT01106859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching zopiclone
Study: NCT02292082
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00896558
Drug: GSK1322322/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1322322/placebo escalating doses from 500mg to 1500mg
Study: NCT04343651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02808052
Drug: Minocin (minocycline) for Injection
Normalized name: minocycline Injection [Minocin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg IV Minocin given over 1 hour
Study: NCT01623596
Drug: Disease Modifying therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01802658
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.
Study: NCT01802658
Drug: NA Cl
Normalized name: China clay
Approvals — FDA: no, EMA: no, PMDA: no
Description: NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
Study: NCT00451035
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02441491
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster.
Study: NCT03354312
Drug: Articaine hydrochloride/epinephrine (adrenaline) hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
Study: NCT02399033
Drug: Xihuang Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
Study: NCT00170768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily tablet (sham titration)
Study: NCT01792713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00924430
Drug: Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin
Normalized name: .alpha.,.beta.'-diglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
Study: NCT00924430
Drug: Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
Study: NCT01944098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00835198
Drug: Dapsone; Tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
Study: NCT00835198
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
Study: NCT04171791
Drug: ABT-199 (venetoclax)
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will be enrolled into the study and receive venetoclax daily per the US FDA package insert guidelines of venetoclax, with dose escalation up to 400 mg. To minimize the risk of tumor lysis syndrome (TLS), and following the package insert directions for dose escalation over 5 weeks, the initial dose is 20 mg daily, and may be progressively increased as tolerated to 400 mg by week 5.
Study: NCT00464061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT01271712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily (od), 3 weeks on/1 week off. Route of administration: oral
Study: NCT01271712
Drug: Best supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
Study: NCT00145184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill taken orally once per day for two months starting at enrollment.
Study: NCT04376684
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive standard of care as per institutional protocol.
Study: NCT03014310
Drug: AS03
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03 oil-in-water emulsion adjuvant.
Study: NCT03014310
Drug: MF59
Normalized name: vaccine adjuvant emulsion MF59C.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
Study: NCT01630252
Drug: PGL5001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection